Abstract:OBJECTIVE:To observe the in vivo therapeutic effects of murine Flt3 ligand (mFL) mediated by recombinant adenoviral vector on murine liver cancer.METHODS:Murine liver cancer cell line Hepal-6 was infected with adenovirus in vitro. The infection efficacy was measured by green fluorescence protein (GFP) expression and the amount of mFL in supernatant was measured by ELISA 48 hrs following infection of Hepal-6. AdmFL, Ad-null, and PBS were added into the culture of Hepal-6 cells, the number of cells was counted every other day for 14 days. A murine liver cancer model was established by subcutaneous inoculation of Hepal-6 cells. A single dosage of 1 x 10(9) expression forming unit (efu) of Ad-mFL, Ad-null or PBS was injected intratumorally. The tumor volume and survival rate were measured twice a week. Twenty days after treatment of adenoviral vectors, three treated mice with their tumor disappearing were killed and their spleen was taken. The splenocytes from these tumor free mice were adoptively transferred to naive mice to whom Hepal-6 cells were inoculated 3 days thereaftter and then the tumor volume was measured once a week.for 4 weeks. 38 days after administration of adenoviral vectors, tumor free animals were rechallenged by parental Hepal-6 cells or syngenic EL4 lymphoma cells at the opposite sites of the original inoculation sites, and the tumor volume was also measured once a week for 4 weeks.RESULTS:Adenoviral vector efficiently infected Hepal-6 cells in intro, and lead to the secretion of high levels of mFL protein (80.5 +/- 7.3 ng/10(6)/24 h) in the supernatant. The growth of Hepal-6 tumor was significantly inhibited by one single intratumoral administration of Ad-mFL in 90% of the treated mice, and the tumor gradually grew in the two other groups. Two of the 7 mice (30%) in PBS group died in 17 days, 14% still lived in 37 days, and all died within 45 days. The mice in the Ad-null group began to die since the 21(st) day, only 11% of them were still alive in 60 days. All mice in the Ad-mFL group were alive at the 60(th) day after tumor implantation. Adoptive transfer of splenocytes to the animals receiving Ad-mFL treatment protected effectively them against a subsequent challenge with the identical tumor cells. Rechallenge of the Ad-mFL cured mice with the parental Hepal-6 cells resulted in complete inhibition of tumor growth. The growth of inoculated EL4 lymphoma cells gradually grew equally in the controls and the experimental mice.CONCLUSION:FL gene transfer mediated by recombinant adenoviral vector has potent therapeutic effects on Hepal-6 liver cancer, and develops long-lasting specific antitumor immunity, which may become a potent cancer gene therapy candidate for further clinic application.

Orally Administered DNA Vaccine Delivery by Attenuated Salmonella typhimurium Targeting Fetal Liver Kinase 1 Inhibits Murine Lewis Lung Carcinoma Growth and Metastasis

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

[Antitumor Effect of Recombinant T7 Phage Vaccine Expressing Xenogenic Vascular Endothelial Growth Factor on Lewis Lung Cancer in Mice].

Construction of a DNA Vaccine against Extracellular Domain 1-3 of Flk1 and Its Inhibitory Effect on Growth of Liver Cancer Cell Line H22

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

Systemic Inhibition of Tumor Growth by Soluble Flk-1 Gene Therapy Combined with Cisplatin

Dendritic cells infected with recombinant adenoviral vector encoding mouse fibroblast activation protein-α and human livin α exert an antitumor effect against Lewis lung carcinoma in mice

Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models

Inhibition of Tumor Growth by Recombinant Adenovirus Containing Human Lactoferrin Through Inducing Tumor Cell Apoptosis in Mice Bearing Emt6 Breast Cancer

Suppression of Breast Tumor Growth by DNA Vaccination Against Phosphatase of Regenerating Liver 3

[Inhibition of mouse Lewis lung cancer via intravenous administration of recombinant mouse sFlt1 adenovirus].

The Enhanced Anti-Angiogenic and Antitumor Effects of Combining Flk1-Based Dna Vaccine and Ip-10

[Gene Transfer of Murine Flt3 Ligand Mediated by Adenoviral Vector Efficiently Induces Growth Inhibition of Murine Liver Cancer].

Suppression of Human MDA-MB-435S Tumor by U6 Promoter-Driven Short Hairpin RNAs Targeting Focal Adhesion Kinase

A DNA Vaccine Expressing an Optimized Secreted FAPα Induces Enhanced Anti-Tumor Activity by Altering the Tumor Microenvironment in a Murine Model of Breast Cancer

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

Preparation of murine lung cancer vaccine modified by macrophagic inflammatory protein 1αand observational study of antitumor activity in vivo

Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation

Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP

Suppression of Tumor Progression and Angiogenesis in Two Lewis Lung Carcinoma Mouse Models by Shrna Knockdown of Fibroblast Activation Protein.

Superior Anti-Tumor Protection and Therapeutic Efficacy of Vaccination with Dendritic Cell/Tumor Cell Fusion Hybrids for Murine Lewis Lung Carcinoma